Plenty of people try a CBD tincture, follow the instructions, and feel nothing. That experience leads a lot of them to write off CBD altogether, when the real issue is often absorption rather than the compound itself.
Arkos Bios approaches this problem as an engineering challenge, building its NanoCBD line around particle size and bioavailability rather than marketing alone. This article looks at what actually makes that approach different and what it means for the products themselves.
Why Standard CBD Oil Often Falls Short
The core problem with traditional CBD oil comes down to basic chemistry. CBD oil molecules are hydrophobic, meaning they repel water, and the body is made mostly of water. Left alone, these molecules clump into large oily clusters roughly 2,000 nanometers across.
Clusters that size are difficult for the body to absorb efficiently, so a significant portion simply passes through the system unused. Standard oil-based CBD is generally estimated at roughly 6 to 10 percent bioavailability, which means most of what is in the bottle never actually reaches the bloodstream.
